Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2014, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital: 5,348,465,058 Ordinary Shares of 25p each.
- Treasury Shares: 489,174,669 Ordinary Shares.
- Total Voting Rights: 4,859,290,389.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. It only states the current capital structure as of the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,859,290,389) against the latest annual report to confirm the denominator for disclosure threshold calculations.
- Confirm the number of shares held in Treasury (489,174,669) to understand the difference between issued capital and voting rights.
- Check subsequent filings for financial performance data, as this specific 6-K contains no financial results.